Subscribe to Cardiovascular
View Sample

FREE Email Newsletter


April 28, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

BERWYN, Pa., April 28, 2011 /- AMETEK, Inc. (NYSE: AME ) today announced that it has acquired Avicenna Technology, Inc., a privately held supplier of custom, fine-featured components used in the medical device industry.  Avicenna Technology with its headquarters and manufacturing...

Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session

April 28, 2011 12:33 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., April 28, 2011 /- Rhythmia Medical Inc., announced today that key results from its ongoing pre-clinical and clinical studies will be presented at the 2011 Annual Scientific Session of the Heart Rhythm Society in San Francisco, CA. The results will highlight the...

NxStage Medical names Miller to new international growth role

April 27, 2011 10:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

NxStage Medical Inc., a Lawrence maker of dialysis products, has named Michael Miller Jr. to the new post of president, international. In the new position, he will be charged with promoting NxStage's global growth in the European Union, Asia-Pacific and the Middle East.


NxStage® Names Michael Miller, Jr. President, International

April 27, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

LAWRENCE, Mass., April 27, 2011 /- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced that Michael Miller, Jr., former Senior Vice President and General Manager of the Cardiac Care Business at Philips Healthcare, has joined the...

Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results

April 26, 2011 11:33 pm | by Bio-Medicine.Org | News | Comments

SEATTLE, April 27, 2011 /- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported accomplishments and financial results for the first quarter ended March 31, 2011. "In the first quarter, we raised $50 million through two financings, advanced pixantrone into...

Idera stock drops on hepatitis-C drug delay

April 26, 2011 6:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Idera Pharmaceuticals Inc.'s stock dropped more than 5 percent Monday, following the company's announcement that it would delay the launch of a clinical trial on its drug candidate for hepatitis C.

Boston Scientific Announces FDA Approval and U.S. Launch of IONâ„¢ Platinum Chromium Stent System

April 25, 2011 4:33 am | by Boston Scientific | News | Comments

Innovative alloy designed to improve new coronary stent's acute performance

Stereotaxis to Present at Upcoming Investor Conferences

April 25, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, April 25, 2011 /- Stereotaxis, Inc. (NASDAQ: STXS ) today announced that executive management will present at the following investor conferences during May 2011: The Deutsche Bank Annual Health Care Conference in Boston.  Michael P. Kaminski, President and Chief Executive...


Two New Studies in the British Medical Journal Find That Bayer's Yaz and Yasmin Birth Control Pills Have an Increased Risk of Blood Clot

April 22, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, April 22, 2011 /PRNewswire-USNewswire/ -- The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto: According to two new studies published in the online edition of the British Medical Journal, Bayer's...

PLC Systems' Chief Financial Officer to Leave Company to Become CEO of Clinquest

April 22, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

FRANKLIN, Mass., April 22, 2011 /- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that its Chief Financial Officer, James G. Thomasch, will leave the company effective May 2, 2011, to become Chief Executive Officer at...

Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Or...

April 22, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

TOKYO, April 22, 2011 /- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and...

ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB®

April 21, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

IRVINGTON, N.Y., April 21, 2011 /- ORTHOCON, Inc., a privately-held therapeutic device company, today announced that DEKRA and Health Canada have cleared its HEMA SORB Absorbable Bone Hemostat Matrix for clinical use and sale in Europe and Canada. HEMA SORB is a ready-to-use,...

Boston Scientific Announces Results for First Quarter Ended March 31, 2011

April 20, 2011 1:33 pm | by Boston Scientific | News | Comments

NATICK, Mass., April 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2011, as well as net sales and earnings per share (EPS) guidance


ABC News Reports on Aethlon Medical

April 20, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, April 20, 2011 /- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it is the subject of an ABC news story that can be accessed online at:...

Cardiogenesis Corporation to Report 2011 First Quarter Results on May 4th

April 20, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., April 20, 2011 /- Cardiogenesis Corporation (OTCQB: CGCP) announced that the company will release results for its first quarter ended March 31, 2011 on Wednesday, May 4, 2011.  The company added that Paul J. McCormick, its Executive Chairman, and William R. Abbott,...

Reportlinker Adds Levosimendan - Comprehensive patent search

April 20, 2011 1:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, April 20, 2011 /- announces that a new market research report is available in its catalogue: Levosimendan - Comprehensive patent search Eliminate unnecessary risk with the...

Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences

April 19, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

SEATTLE, April 19, 2011 /- Omeros Corporation (NASDAQ: OMER ) today announced that research on mannan-binding lectin-associated serine protease-2 (MASP-2) has been published in the April 18, 2011 Early Online Edition of the Proceedings of the National Academy of Sciences (PNAS)....

Abaxis to Report Fourth Quarter and Fiscal Year 2011 Financial Results Thursday, April 28, 2011

April 19, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

UNION CITY, Calif., April 19, 2011 /- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2011, ended March 31, 2011. The call...

Cumberland Pharmaceuticals Announces New Product Addition With Hepatorenâ„¢ (ifetroban) Injection

April 19, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

NASHVILLE, Tenn., April 19, 2011 /- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II...

CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation

April 18, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

ATLANTA and IRVINE, Calif., April 18, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the expiration of the 20-day "go-shop" period that is part of its definitive agreement with Cardiogenesis...

Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient

April 18, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

GAITHERSBURG, Md., April 18, 2011 /- Sigma-Tau Pharmaceuticals, Inc. is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture L-asparaginase, the primary ingredient in the oncology medicine ONCASPAR® (pegaspargase)....

$210M Pfizer Deal Validates Small Firm

April 17, 2011 11:33 pm | by San Diego Business Journal | News | Comments

Robin Jackman, Zacharon's president and CEO, is the first to admit that there aren't too many people outside the biotech world who understand the science at the core of his small company.

Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and S...

April 17, 2011 10:34 pm | by Bio-Medicine.Org | News | Comments

MYSTIC, Conn. and DUBLIN, April 18, 2011 /- Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product...

Atrium Provides Grant to Establish Education Web Site at

April 15, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

HUDSON, N.H., April 15, 2011 /- Atrium Medical Corporation has provided an educational grant to establish an educational web site, Atrium University, at .  "Atrium has been proud to be the market leader in educational support for our customers," said Jeff McGill,...

New Test Spots Infections in Hours, Rather than Days

April 14, 2011 8:34 pm | by Massachusetts Institute of Technology | News | Comments

A startup has developed a device that uses magnetic particles to identify pathogens rapidly.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.